Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAMK2D shRNA
- Development stage
- Preclinical
- Lead developer
- NYU Grossman School of Medicine
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
CAMK2D shRNA is a short hairpin RNA therapeutic candidate designed to specifically target and silence the expression of the CAMK2D (Calcium/calmodulin-dependent protein kinase II delta) isoform. In the context of glioblastoma (GBM), CAMK2D has been identified as a key effector of spontaneous calcium waves that drive tumor growth. By utilizing RNA interference to reduce CAMK2D mRNA levels, this shRNA impairs the clonogenic potential and tumorsphere formation of patient-derived glioblastoma cultures. Research conducted at the NYU Grossman School of Medicine suggests that CAMK2D knockdown significantly reduces tumor growth, highlighting its potential as a therapeutic target for primary brain malignancies.
- Other names
- CAMK2D-specific shRNACAMK-2D-specific shRNACAMK 2D-specific shRNACAMK2D knockdownCAMK-2D knockdownCAMK 2D knockdown
02
Targets
CAMK2D (Calcium/calmodulin-dependent protein kinase II delta)
Beyond the preview
Go deeper on CAMK2D shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAMK2D shRNA.